PMID- 10516115
OWN - NLM
STAT- MEDLINE
DCOM- 19991122
LR  - 20181002
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 277
IP  - 4
DP  - 1999 Oct
TI  - Pharmacokinetics of insulin-like growth factor I in hypopituitarism: correlation 
      with binding proteins.
PG  - E579-84
LID - 10.1152/ajpendo.1999.277.4.E579 [doi]
AB  - We investigated the pharmacokinetics of recombinant human insulin-like growth 
      factor I (rhIGF-I) in growth hormone deficiency (GHD). Nine GHD adults [age 25 
      +/- 3 (SE) yr] received rhIGF-I (60 microgram/kg sc) twice, 10 h apart, and blood 
      was sampled over 24 h. IGF-I and free IGF-I concentrations increased, whereas IGF 
      binding protein 3 (IGFBP-3) and acid labile subunit (ALS) were unchanged during 
      treatment. There was no correlation between absorption or terminal half-life of 
      IGF-I and IGFBP-3 or ALS, but negative correlations with IGF-I clearance (CL/F) 
      and volume of distribution (V/F). Positive correlations between both IGFBP-3 and 
      ALS and IGF-I maximal concentration (C(max)) and time of C(max) (T(max)) were 
      observed. Compared with normal individuals studied similarly (using 80 
      microgram/kg), GHD subjects showed a normal absorption half-life, a faster 
      elimination half-life, lower C(max), yet normal T(max) and V/F. In conclusion, 
      GHD is associated with normal absorption and distribution of IGF-I yet faster 
      elimination kinetics. Additionally, IGFBP-3 and ALS concentrations modulate the 
      peak concentrations of IGF-I achieved and correlate reciprocally with its V/F and 
      CL/F, underscoring the critical importance of binding proteins in modulating the 
      bioavailability of IGF-I in vivo in humans.
FAU - Mauras, N
AU  - Mauras N
AD  - Nemours Children's Clinic, Jacksonville, Florida 32207, USA.
FAU - Quarmby, V
AU  - Quarmby V
FAU - Bloedow, D C
AU  - Bloedow DC
LA  - eng
GR  - R01-DK-51360/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Carrier Proteins)
RN  - 0 (Glycoproteins)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 0 (Insulin-Like Growth Factor Binding Proteins)
RN  - 0 (Recombinant Proteins)
RN  - 0 (insulin-like growth factor binding protein, acid labile subunit)
RN  - 12629-01-5 (Human Growth Hormone)
RN  - 67763-97-7 (Insulin-Like Growth Factor II)
RN  - 9002-72-6 (Growth Hormone)
SB  - IM
MH  - Absorption
MH  - Adolescent
MH  - Adult
MH  - Carrier Proteins/blood
MH  - Female
MH  - Glycoproteins/blood
MH  - Growth Hormone/*deficiency
MH  - Half-Life
MH  - Human Growth Hormone/analysis/*pharmacokinetics
MH  - Humans
MH  - Hypopituitarism/blood/*metabolism
MH  - Insulin-Like Growth Factor Binding Protein 3/blood
MH  - Insulin-Like Growth Factor Binding Proteins/*blood
MH  - Insulin-Like Growth Factor II/analysis
MH  - Male
MH  - Osmolar Concentration
MH  - Recombinant Proteins/blood/pharmacokinetics
EDAT- 1999/10/12 00:00
MHDA- 1999/10/12 00:01
CRDT- 1999/10/12 00:00
PHST- 1999/10/12 00:00 [pubmed]
PHST- 1999/10/12 00:01 [medline]
PHST- 1999/10/12 00:00 [entrez]
AID - 10.1152/ajpendo.1999.277.4.E579 [doi]
PST - ppublish
SO  - Am J Physiol. 1999 Oct;277(4):E579-84. doi: 10.1152/ajpendo.1999.277.4.E579.